New Options for Transplant-Ineligible or Deferred Multiple Myeloma Patients: Recent Trial Insights
Dr. Marc Braunstein explores CEPHEUS trial results, advancing care for transplant-ineligible multiple myeloma patients. Live Q&A included! RHealthTree Foundation offers trusted education, community support, and a powerful data portal for Multiple Myeloma patients. Join our newsletter to stay informed of future myeloma webinars https://htree.org/myelomanews Follow HealthTree https://x.com/HealthTree / healthtreeformultiplemyeloma / healthtreeformultiplemyeloma
▶︎
Recent Advances in Multiple Myeloma with Dr. Dan Vogl
▶︎
Myeloma 101: Understanding Multiple Myeloma, Risk Factors, Diagnosis & Treatments Explained
▶︎
Your Multiple Myeloma Lab Results, Decoded: What They Mean and What They Don’t
▶︎
Is MRD Negativity the End Goal? Understanding When/Why It's Important
▶︎
Blood, bones and the tip of the iceberg: Myeloma markers and monitoring
▶︎
Former nurse speaks out after sentencing in fatal drug error | Nightline
▶︎
Ciltacabtagene Autoleucel (CARVYKTI) - a BCMA-Directed CAR T-Cell Therapy for Multiple Myeloma
▶︎
Can a keto diet eliminate cancer growth? Dr. Thomas Seyfried says yes
▶︎
VMP ± Dara versus Rd ± Dara in transplant-ineligible patients with myeloma: a Phase IV trial
▶︎
Innovations in Myeloma Therapies: Promise of ADCs, CELMoDs, BCL2 Inhibitors, & SINEs | Dan Vogl, MD
▶︎
Relapsed Multiple Myeloma: What Every Patient Needs to Know
▶︎
Plasma Cell Disorders | Clinical Medicine
▶︎
Everything You Need to Know About Multiple Myeloma - Episode 1 of 2
▶︎
Int'l Neuroblastoma Webinar Series Session #18: BCC Clinical Trials Update with Dr. Giselle Sholler
▶︎
SUCCESSOR-2 Trial: Mezigdomide Triplet Shows Powerful Results in Relapse/Refractory Multiple Myeloma
▶︎
Diagnosed with High-Risk Myeloma: What Now?
▶︎
ASH 2025 Comes to You! - with Adam Kittai, MD and Brian Koffman, MDCM (retired) MS Ed
▶︎
The Immune System in Myeloma: How It Shapes Treatment and Outcomes
▶︎
Multiple Myeloma 101 for 2025: Diagnosis, Prognosis, and Risk
▶︎